| Roche Pharma (Schweiz) AG - Madopar 125, Tabletten | | 43593 | | 02 | | Madopar 125 | | Tabletten | | N04BA02 | | Levodopa and Decarboxylase Inhibitor | | 20.05.1987 | | |
| | Composition | | levodopum 100.00 mg, benserazidum 25.00 mg ut benserazidi hydrochloridum, mannitolum, calcii hydrogenophosphas, cellulosum microcristallinum, amylum pregelificatum, crospovidonum, ethylcellulosum, E 172 (rubrum), silica colloidalis anhydrica, natrii docusas corresp. natrium 0.005 mg, magnesii stearas, pro compresso. | | Packungsbestandteile | | Tablets | | | | | Active Agent | Dose |
|---|
| Benserazide | 25 mg | | Levodopa | 100 mg |
| | BAG: Active Agent | Dose |
|---|
| Benserazide | 25 mg | | Levodopa | 100 mg |
| | | | Inactive agents | | additional_information |
|---|
| | | | | | | | | Calcium Hydrogen Phosphate | | | | | | | | | | | | | | color. | | | | | | | | | | Mannitol | | | | Natrii Docusas | | | | | | | | Silica Colloidalis Anhydrica | | |
| |
| | Teilbarkeit | | | Ja (Bruchrille) | | | | Ja | | | | Ja | | | | -- | | | | Die Tabletten weisen eine Kreuzbruchrille auf, instabiler Wirkstoff. Vorschlag: Madopar LIQ (= wasserlösliche Tabletten) verwenden. [2] | | | | | [2] Firmeninformation |
| |
|
